# Evotec SE

Evotec SE is a Biotechnology based in Hamburg, Germany.

## Overview

- **Organization type:** Biotechnology
- **Headquarters:** Hamburg, Germany
- **Region:** North America
- **Address:** Hamburg, Germany
- **Founded:** 1993
- **Assets under management:** Undisclosed
- **Website:** evotec.com
- **LinkedIn:** https://www.linkedin.com/company/evotec

## Regulatory record

- **Reports private funds:** No

## About

Evotec SE was founded in 1993 by a team of scientists and has grown into a publicly traded company on the Frankfurt Stock Exchange, with Werner Lanthaler as CEO since 2007. The firm's wealth origin is tied to its public equity issuance and operational revenue, not a single family fortune. Evotec's strategy centers on drug discovery and development, spanning small molecules, biologics, and gene therapies. The firm operates through joint ventures and partnerships, including a 2022 collaboration with Bristol Myers Squibb to develop new therapies (per Evotec, 2022) and a 2021 alliance with Novo Nordisk for diabetes treatments (per Evotec, 2021). Geographic footprint includes offices in Hamburg, Germany, Pasadena and Palo Alto, California, Houston, Texas, Cambridge, Massachusetts, and Mississauga, Canada. Evotec employs over 4,000 professionals across its global offices, with a team of scientists, data analysts, and business development managers. The firm has established an AI/ML platform, Evotec Ai, to enhance drug discovery efficiency. In 2023, Evotec launched a partnership with the Helmut Horten Foundation for neurodegenerative disease research (per Evotec, 2023). A structural differentiator is Evotec's hybrid model as a publicly traded company with service-based and co-development partnerships, rather than a venture capital or private equity fund. This allows it to access public markets for capital while maintaining operational focus on R&D collaborations, with a governance structure overseen by a board of directors and shareholders.

## Sectors

- Digital Health
- AI/ML
- ClimateTech
- Industrial Tech
- Infrastructure

## Offices

- Pasadena, CA, United States
- Palo Alto, CA, United States
- Houston, TX, United States
- Cambridge, MA, United States
- Mississauga, ON, Canada

## People

- Werner Lanthaler — Chief Executive Officer
- Mario Polywka — Chief Operating Officer
- Enno Spillner — Chief Financial Officer

## Questions

### Who runs investment decisions at Evotec SE?

CEO Werner Lanthaler leads overall strategy, with investment decisions guided by an executive board and scientific advisory team. The firm's publicly traded status means major financial moves require shareholder approval, distinct from a private family office.

### How does Evotec SE source proprietary deal flow?

Evotec sources deals through its internal business development team and scientific network, focusing on joint ventures and partnerships with pharmaceutical companies and biotech startups. The firm leverages its AI platform, Evotec Ai, to identify and validate therapeutic targets (per Evotec, 2023).

### Does Evotec SE participate in fund commitments or only direct deals?

Evotec primarily engages in direct deals through joint ventures and service agreements, rather than committing to external funds. It has established partnerships with major pharmaceutical firms like Bristol Myers Squibb and Novo Nordisk (per Evotec, 2022; 2021).

### What investment stages does Evotec SE typically target?

Evotec focuses on preclinical and clinical-stage drug development, from target identification through Phase II trials. The firm collaborates on early-stage research and later-stage partnerships, depending on the partner's needs.

## Related profiles

- [BARDA](https://altss.com/profile/biomedical-advanced-research-and-development-authority)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/evotec-se

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology